Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letaplimab + HMAs in AML
NCT04485052Phase 2Suspended
- Sponsor
- Innovent Biologics
- Start
- Sep 2020
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of letaplimab in acute myeloid leukemia (AML), sponsored by Innovent Biologics. Started Sep 2020; status: suspended.
02
Drugs
letaplimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04485052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04485052.